CD47 and glioblastoma: The therapeutic safety and efficacy of anti-CD47 treatment was also demonstrated in mouse models of murine high-grade glioma as well as five aggressive and etiologically distinct human pediatric brain tumors (medulloblastoma, atypical teratoid/rhabdoid tumor, primitive neuroectodermal tumor, pediatric GBM, and diffuse intrinsic pontine glioma) (121).